Breast cancer has been one area where checkpoint inhibitors have not yet gained traction – but that might be about to change following results announced by Tesaro at the American Society of
Merck & Co has dominated proceedings at the American Society of Clinical Oncology (ASCO), with a steady flow of data from its Keytruda checkpoint inhibitor drug at the conference in Chi
Bristol-Myers Squibb is hoping to revive its Opdivo cancer immunotherapy by combining it with an experimental agent from Nektar Therapeutics. But new early stage data from the cocktail pres
Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in non-small cell lung cancer (NSCLC).
Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.
